Preexposure Prophylaxis (PrEP) for HIV Prevention at Outpatient Substance Use Treatment Facilities, United States, 2021
American Journal of Public Health · 2024
DOI: 10.2105/ajph.2024.307699 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Public Health, 2024. Verfasst von Samuel R Bunting und 3 weiteren Autor:innen. Beteiligte Einrichtung: Samuel Bunting is with the Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL. Nitin Vidyasagar is with the Pri…. Hauptthemen laut MEDLINE: HIV Infections, Pre-Exposure Prophylaxis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS.
Abstract (Originalsprache)
Objectives
To determine the percentage of US outpatient substance use treatment facilities that offer HIV preexposure prophylaxis (PrEP).
Methods
We used a retrospective cross-sectional design with data from the National Substance Use and Mental Health Services Survey, which was administered to directors of US outpatient substance use treatment facilities in 2021. We evaluated the percentage of outpatient substance use treatment facilities offering PrEP and factors associated with the likelihood of offering PrEP.
Results
We included 12 182 outpatient substance use treatment facilities. Of these, 637 (5.2%) offered PrEP. Offering HIV treatment (adjusted odds ratio [AOR] = 45.3; 95% confidence interval [CI] = 36.0, 56.9) and offering programs for LGBTQ (lesbian, gay, bisexual, transgender, and queer or questioning) people (AOR = 1.3; 95% CI = 1.0, 1.6) were associated with higher likelihoods of offering PrEP.
Conclusions
PrEP is highly effective and recommended for patients at risk for HIV from injection drug use. Nearly 95% of US outpatient substance use treatment facilities did not offer PrEP—a missed opportunity for harm reduction through primary HIV prevention. Public Health Implications. Diversification of the array of available HIV PrEP options and the ongoing HIV and opioid use epidemics require outpatient substance use treatment facilities to expand PrEP availability. ( Am J Public Health. 2024;114(8):833–837. https://doi.org/10.2105/AJPH.2024.307699 )
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Samuel Bunting is with the Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL. Nitin Vidyasagar is with the Pritzker School of Medicine, University of Chicago. Allison Wilson and An…
Förderung
- NIMH NIH HHS
Zitieren
APA
Bunting, S. R., Vidyasagar, N., Wilson, A. P., & Hazra, A. (2024). Preexposure Prophylaxis (PrEP) for HIV Prevention at Outpatient Substance Use Treatment Facilities, United States, 2021. American Journal of Public Health. https://doi.org/10.2105/ajph.2024.307699
Vancouver
Bunting SR, Vidyasagar N, Wilson AP, Hazra A. Preexposure Prophylaxis (PrEP) for HIV Prevention at Outpatient Substance Use Treatment Facilities, United States, 2021. American Journal of Public Health. 2024. doi:10.2105/ajph.2024.307699
BibTeX
@article{Bunting2024,
author = {Bunting, Samuel R and Vidyasagar, Nitin and Wilson, Allison P and Hazra, Aniruddha},
title = {Preexposure Prophylaxis (PrEP) for HIV Prevention at Outpatient Substance Use Treatment Facilities, United States, 2021},
journal = {American Journal of Public Health},
year = {2024},
doi = {10.2105/ajph.2024.307699}
}
EUVIMED